ML213 and NS15370 are potent vasorelaxants in rat blood vessels, acting via a tryptophan residue in the S5 domain, highlighting their potential as therapeutics for smooth muscle disorders.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for Kv7 enhancers in vascular disorders; human studies required before therapeutic consideration.
Jepps et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: